癫痫研究取得积极结果后Ovid上升

2025-10-03 21:26

Ovid Therapeutics (NASDAQ:OVID) stock rose after encouraging results from its early stage study testing its experimental candidate, OV329, aimed at treating drug-resistant epilepsy.
Stock is up 24% premarket.
The results of the study showed that OV329 significantly inhibits GABA-AT, as evidenced by various measurements.
In the study, OV329 demonstrated a favorable safety and tolerability profile, with all potentially treatment-related adverse events reported as mild and transient.
Looking ahead, Ovid plans to move OV329 into a Phase 2a trial targeting drug-resistant focal onset seizures.
Additionally, the company is set to complete a final study to support regulatory submissions for its first oral KCC2 direct activator, OV4071, anticipated in early 2026.

More on Ovid Therapeutics